Observational studyJournal of cardiovascular electrophysiology2025
Sotalol Dosing and Outcomes Among Patients Undergoing Intravenous Loading for Atrial Arrhythmias-A PEAKS Registry Substudy.
Observational study in Journal of cardiovascular electrophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05247320 (Prospective Evaluation Analysis and Kinetics of IV Sotalol), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Evaluation Analysis and Kinetics of IV Sotalol
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundSotalol is used for the maintenance of sinus rhythm among patients with atrial fibrillation. However, there is discretion regarding dosing of chronic therapy, and the target oral dose dictates infusion doses for intravenous sotalol loading. To date, use and outcomes by dose are not well-described.
methodsIn the Prospective Evaluation Analysis and Kinetics of IV Sotalol (PEAKS) Registry, we analyzed outcomes among patients undergoing elective IV sotalol load for atrial arrhythmias (AT/AF). Baseline characteristics, changes in ECG parameters, in-hospital adverse events, and arrhythmia outcomes were compared based on target oral dose (80 mg vs. 120 mg).
resultsAmong 163 total patients, 85 (52%) of patients underwent loading anticipating target oral dose of 80 mg, compared with 78 (48%) for 120 mg. Those targeting 80 mg were older (median age 70 vs. 66, p < 0.001), with similar proportion female (24% vs. 21%, p = 0.71), and without significant differences in comorbidities or renal function. Patients targeted for 80 mg were less frequently kept in-hospital for 2 oral doses after intravenous infusion (45% vs. 89%, p < 0.001). There were no significant differences in rates of sinus rhythm or adverse events during loading.
conclusionsSelection of target oral sotalol dose (120 vs. 80 mg) does not appear to be driven by patient characteristics, and may represent an opportunity for improved treatment. In-hospital adverse events are low overall without differences between dose.
trial registrationClinicaltrials. gov # NCT05247320.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.